BACKGROUND: The present study evaluated the reversal of diabetes-mediated impairment of angiogenesis in a myocardial infarction model of type 1 diabetic rats by intramyocardial administration of an adenoviral vector encoding thioredoxin-1 (Ad.Trx1). Various studies have linked diabetes-mediated impairment of angiogenesis to dysfunctional antioxidant systems in which thioredoxin-1 plays a central role. METHODS AND RESULTS: Ad.Trx1 was administered intramyocardially in nondiabetic and diabetic rats immediately after myocardial infarction. Ad.LacZ was similarly administered to the respective control groups. The hearts were excised for molecular and immunohistochemical analysis at predetermined time points. Myocardial function was measured by echocardiography 30 days after the intervention. The Ad.Trx1-administered group exhibited reduced fibrosis, oxidative stress, and cardiomyocyte and endothelial cell apoptosis compared with the diabetic myocardial infarction group, along with increased capillary and arteriolar density. Western blot and immunohistochemical analysis demonstrated myocardial overexpression of thioredoxin-1, heme oxygenase-1, vascular endothelial growth factor, and p38 mitogen-activated protein kinase-beta, as well as decreased phosphorylated JNK and p38 mitogen-activated protein kinase-alpha, in the Ad.Trx1-treated diabetic group. Conversely, we observed a significant reduction in the expression of vascular endothelial growth factor in nondiabetic and diabetic animals treated with tin protoporphyrin (SnPP, a heme oxygenase-1 enzyme inhibitor), even after Ad.Trx1 therapy. Echocardiographic analysis after 4 weeks of myocardial infarction revealed significant improvement in myocardial functional parameters such as ejection fraction, fractional shortening, and E/A ratio in the Ad.Trx1-administered group compared with the diabetic myocardial infarction group. CONCLUSIONS: This study demonstrates for the first time that impairment of angiogenesis and myocardial dysfunction can be regulated by Ad.Trx1 gene therapy in streptozotocin-induced diabetic rats subjected to infarction.
BACKGROUND: The present study evaluated the reversal of diabetes-mediated impairment of angiogenesis in a myocardial infarction model of type 1 diabeticrats by intramyocardial administration of an adenoviral vector encoding thioredoxin-1 (Ad.Trx1). Various studies have linked diabetes-mediated impairment of angiogenesis to dysfunctional antioxidant systems in which thioredoxin-1 plays a central role. METHODS AND RESULTS:Ad.Trx1 was administered intramyocardially in nondiabetic and diabeticrats immediately after myocardial infarction. Ad.LacZ was similarly administered to the respective control groups. The hearts were excised for molecular and immunohistochemical analysis at predetermined time points. Myocardial function was measured by echocardiography 30 days after the intervention. The Ad.Trx1-administered group exhibited reduced fibrosis, oxidative stress, and cardiomyocyte and endothelial cell apoptosis compared with the diabetic myocardial infarction group, along with increased capillary and arteriolar density. Western blot and immunohistochemical analysis demonstrated myocardial overexpression of thioredoxin-1, heme oxygenase-1, vascular endothelial growth factor, and p38 mitogen-activated protein kinase-beta, as well as decreased phosphorylated JNK and p38 mitogen-activated protein kinase-alpha, in the Ad.Trx1-treated diabetic group. Conversely, we observed a significant reduction in the expression of vascular endothelial growth factor in nondiabetic and diabetic animals treated with tin protoporphyrin (SnPP, a heme oxygenase-1 enzyme inhibitor), even after Ad.Trx1 therapy. Echocardiographic analysis after 4 weeks of myocardial infarction revealed significant improvement in myocardial functional parameters such as ejection fraction, fractional shortening, and E/A ratio in the Ad.Trx1-administered group compared with the diabetic myocardial infarction group. CONCLUSIONS: This study demonstrates for the first time that impairment of angiogenesis and myocardial dysfunction can be regulated by Ad.Trx1 gene therapy in streptozotocin-induced diabeticrats subjected to infarction.
Authors: M Noa Valcarcel-Ares; Tripti Gautam; Junie P Warrington; Lora Bailey-Downs; Danuta Sosnowska; Rafael de Cabo; Gyorgy Losonczy; William E Sonntag; Zoltan Ungvari; Anna Csiszar Journal: J Gerontol A Biol Sci Med Sci Date: 2012-01-04 Impact factor: 6.053
Authors: Qunhua Huang; Huanjiao Jenny Zhou; Haifeng Zhang; Yan Huang; Ford Hinojosa-Kirschenbaum; Peidong Fan; Lina Yao; Luiz Belardinelli; George Tellides; Frank J Giordano; Grant R Budas; Wang Min Journal: Circulation Date: 2015-01-27 Impact factor: 29.690
Authors: Vaithinathan Selvaraju; Sumanth C Suresh; Mahesh Thirunavukkarasu; Jayakanthan Mannu; Jocelyn L C Foye; Premendu P Mathur; J Alexander Palesty; Juan A Sanchez; David W McFadden; Nilanjana Maulik Journal: J Cardiovasc Transl Res Date: 2017-03-09 Impact factor: 4.132
Authors: Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth Journal: Cell Mol Life Sci Date: 2018-01-11 Impact factor: 9.261
Authors: Anna Csiszar; Tripti Gautam; Danuta Sosnowska; Stefano Tarantini; Eszter Banki; Zsuzsanna Tucsek; Peter Toth; Gyorgy Losonczy; Akos Koller; Dora Reglodi; Cory B Giles; Jonathan D Wren; William E Sonntag; Zoltan Ungvari Journal: Am J Physiol Heart Circ Physiol Date: 2014-06-06 Impact factor: 4.733
Authors: Anna Csiszar; Danuta Sosnowska; Zsuzsanna Tucsek; Tripti Gautam; Peter Toth; Gyorgy Losonczy; Ricki J Colman; Richard Weindruch; Rozalyn M Anderson; William E Sonntag; Zoltan Ungvari Journal: J Gerontol A Biol Sci Med Sci Date: 2012-08-17 Impact factor: 6.053